Clinical trials: Impairment
Hepatic Insufficiency, Healthy
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female…
- Trial name
- NCT05440344
- Testing
- Imlunestrant
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Persistent Allergic Asthma
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 National Heart, Lung, and Blood…
- Trial name
- NCT00870584
- Testing
- Omalizumab
- Where
- 50 sites in United States
- Volunteers
- 271 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at…
- Trial name
- DERIVE (NCT02413398)
- Testing
- Dapagliflozin 10 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 321 people
- Sponsor
- AstraZeneca
Renal Insufficiency, Chronic, Hepatic Insufficiency
Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects
An open-label, single-dose study to evaluate the safety and pharmacokinetics of DIC075V in subjects with mild or moderate chronic renal insufficiency and in patients with mild chronic hepatic impairment compared.
- Conditions
- Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
- Trial name
- NCT00805090
- Testing
- Sporanox, Diclofenac Sodium
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Javelin Pharmaceuticals
Renal Impairment, Healthy
Study of ALXN2050 in Participants With Renal Impairment
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with impaired renal function.
- Trial name
- NCT04623710
- Testing
- ALXN2050
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myelofibrosis
PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects
This is a Phase 1 open label, single dose, 5 parallel-group study in which a single 400 mg dose of pacritinib will be administered orally to patients with renal impairment (mild, moderate, severe, and patients with ESRD requiring…
- Trial name
- NCT02807077
- Testing
- Pacritinib
- Where
- 3 sites in Germany, Moldova and 1 more
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Alzheimer's Disease
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test…
- Trial name
- NCT01561430
- Testing
- LY2886721
- Where
- 34 sites in United States, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Hepatic Impairment
Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
This study is designed investigate the effect of severe hepatic impairment on the pharmacokinetics (PK) of cenobamate.
- Trial name
- NCT04791553
- Testing
- Cenobamate
- Where
- 2 sites in Poland, Slovakia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- SK Life Science, Inc.
Mild Cognitive Impairment
Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
- Trial name
- NCT02211560
- Testing
- Phosphatidylserine
- Where
- 15 sites in United States, Israel
- Volunteers
- 97 people
- Sponsor
- Enzymotec
Patients With Impaired Renal Function
Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function
The objective of this study is to compare the pharmacokinetics of ASP015K in patients with impaired renal function and subjects with normal renal function.
- Trial name
- NCT02603497
- Testing
- ASP015K
- Where
- 2 sites in Japan
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Renal Impairment
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with severe renal impairment and moderate renal…
- Trial name
- NCT06742762
- Testing
- AZD5004
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hepatic Impairment
Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
This study is designed to evaluate the effect of severe hepatic impairment on the pharmacokinetics (PK) of telotristat ethyl (TE) ( LP-778902 active moiety, metabolite), following administration of a single dose of TE 250 mg (1 x…
- Trial name
- NCT03423446
- Testing
- Telotristat Ethyl
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Alzheimer's Disease
A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects
This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers, MCI and AD subjects provide the same results.
- Trial name
- NCT01992380
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Renal Impairment
The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
The study will investigate the impact of reduced renal function on the pharmacokinetic and pharmacodynamic profile of LEO 27847.
- Trial name
- NCT01141179
- Testing
- LEO 27847
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Hepatic Insufficiency
A Study of Tirzepatide in Participants With Impaired Liver Function
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.
- Trial name
- NCT03940742
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI)
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
The goal of this study is to learn if medical image analysis software, Neurophet SCALE PET, can enhance readers' amyloid beta positivity performance in people with Alzheimer's Disease.
- Trial name
- NCT07417540
- Testing
- Neurophet SCALE PET
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- NEUROPHET
Renal Insufficiency
A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems
This study is open to people with and without kidney problems. People can join the study if they are 18 years or older and have a body mass index (BMI) between 18.5 and 35 kg/m2.
- Trial name
- NCT05718843
- Testing
- BI 425809
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.